Foresee Pharmaceuticals spots prostate cancer med's potential in rare puberty disease, touts phase 3 win

Foresee Pharmaceuticals Camcevi, currently approved as a treatment for advanced prostate cancer, showed promise in a phase 3 study that enrolled children with central precocious puberty (CPP).